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Abstract 
Background: The phase III randomized FALCON trial (NCT01602380) demonstrated 
improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in 
endocrine therapy-naïve postmenopausal women with hormone receptor-positive (HR+) 
locally advanced or metastatic breast cancer (LA/MBC). Furthermore, overall health-related 
quality of life (HRQoL) was maintained and comparable for fulvestrant and anastrozole. 
Here, we present additional analyses of patient-reported HRQoL outcomes from FALCON. 
Methods: Women with endocrine therapy-naïve HR+ LA/MBC were randomized 1:1 to 
fulvestrant (days 0, 14, 28, then every 28 days) or anastrozole (daily) until disease 
progression or discontinuation. HRQoL was assessed by FACT-B questionnaire (TOI and 
FACT-B total score) at randomization and every 12 weeks during treatment. HRQoL data 
post-treatment (with or without progression) were also collected.  
Results: In total, 462 patients were randomized (fulvestrant, n = 230; anastrozole, n = 232). 
Compliance to FACT-B overall ranged from 60.0–97.4%. Mean change from baseline in TOI 
and FACT-B total score remained broadly stable (approximately ± 3 points to week 132) and 
was similar between arms during treatment. HRQoL was also maintained in FACT-B 
subscales. Approximately one-third of patients had improved TOI (≥+6 points) and FACT-B 
(≥+8 points) total scores from baseline up to week 120 and 132, respectively, of treatment 
with fulvestrant (ranges 26.4–45.0% and 22.4–35.8%, respectively) and anastrozole 
(ranges 18.6–32.9%, and 22.7–37.9%, respectively). 
Conclusions: Mean change from baseline in TOI and FACT-B total score was maintained for 
fulvestrant and anastrozole; similar proportions of patients in both arms had improved TOI 
and FACT-B total scores. 
ClinicalTrials.gov identifier: NCT01602380 
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1. Introduction 
Endocrine monotherapy is the recommended first-line treatment for the majority of 
postmenopausal patients with hormone receptor-positive (HR+), locally advanced or 
metastatic breast cancer (LA/MBC) [1–3]. First-line treatment options that are currently 
recommended include tamoxifen or an aromatase inhibitor (AI), such as anastrozole, 
letrozole, or exemestane, fulvestrant, and the cyclin-dependent kinase 4/6 inhibitor 
palbociclib in combination with an AI [1–3]. Fulvestrant is a selective oestrogen-receptor 
degrader that blocks oestrogen-receptor function [4], and was originally approved by the 
European Medicines Agency for the treatment of postmenopausal patients with HR+ 
LA/MBC, and by the United States Food and Drug Administration for postmenopausal 
women with HR+ MBC, who have progressed on prior anti-oestrogen therapy [5,6]. 
Fulvestrant is also approved in the USA and Europe for the treatment of patients with HR+ 
human epidermal growth factor 2-negative advanced or MBC in combination with 
palbociclib, and in the USA with abemaciclib, following disease progression on prior 
endocrine therapy [6]. 
In the double-blind, randomized phase III Fulvestrant and Anastrozole Compared in 
Hormonal Therapy Naïve Advanced Breast Cancer (FALCON) trial (NCT01602380), 
fulvestrant 500 mg demonstrated significantly improved progression-free survival (PFS) 
versus anastrozole 1 mg in postmenopausal women with HR+ LA/MBC who had not 
received prior endocrine therapy (hazard ratio [HR] = 0.797; 95% confidence interval [CI]: 
0.637–0.999; P = 0.0486) [7]. These data confirmed the results of the phase II, randomized, 
open-label FIRST (Fulvestrant First-Line Study Comparing Endocrine Treatments) study 
(NCT00274469), which reported that fulvestrant 500 mg improved time to disease 
progression and overall survival compared with anastrozole 1 mg for the first-line treatment 
of postmenopausal women with HR+ LA/MBC [8–10]. 
6 
 
Following these findings, fulvestrant received regulatory approval in Europe, Russia, 
Japan and the USA for the first-line treatment of postmenopausal women with LA/MBC.  
In addition to delaying progression and prolonging survival, a further aim of treatment 
for HR+ LA/MBC is to optimize health-related quality of life (HRQoL) [1,2]. HRQoL 
outcomes are now considered to be important endpoints in cancer clinical trials [11,12]. 
Indeed, consideration of HRQoL for patients with LA/MBC is recommended in treatment 
guidelines [1,2] and may support regulatory submissions [13,14]. This is particularly relevant 
considering the approval of fulvestrant as a combination therapy with palbociclib [6] and 
abemaciclib [15], as patients with MBC may receive multiple therapies, potentially affecting 
adverse-event (AE) profiles and HRQoL. Furthermore, given that HRQoL can be a 
prognostic indicator, it is important that clinicians consider HRQoL in clinical decision-
making [16].  
HRQoL with fulvestrant has previously been evaluated in the second-line setting. 
Results of the phase III, randomized, double-blind Comparison of Faslodex in Recurrent or 
Metastatic Breast Cancer (CONFIRM) study that compared fulvestrant 250 and 500 mg 
demonstrated that no significant difference in HRQoL was detected between the two study 
arms, as determined by the Functional Assessment of Cancer Therapy for Breast Cancer 
(FACT-B)-derived Trial Outcome Index (TOI) [17]. In the second-line PALOMA-3 study, 
global HRQoL scores and improvement from baseline in pain were significantly improved 
with fulvestrant plus palbociclib versus fulvestrant plus placebo. No significant differences 
were reported for the European Organisation for Research and Treatment of Cancer Quality-
of-Life questionnaire breast cancer module (EORTC QLQ-BR23) functioning domains, 
breast or arm symptoms [18]. 
In the first-line setting, evaluation of HRQoL with fulvestrant was not included in the 
FIRST study; therefore, the FALCON study was the first to assess overall HRQoL with first-
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line fulvestrant. Using the validated FACT-B questionnaire [19] total score and the TOI, 
results suggested that HRQoL was maintained and similar for fulvestrant and anastrozole [7]. 
There was no evidence of a detriment with fulvestrant versus anastrozole in time to 
deterioration (TTD) for both FACT-B total score (HR = 0.84; 95% CI: 0.66–1.07; 
P = 0.1594) and TOI (HR = 0.90; 95% CI: 0.70–1.15; P = 0.4008) [7]. 
Here, additional post-hoc analyses of patient-reported HRQoL outcomes from the 
FALCON study are presented. 
2. Methods 
2.1. Study design 
The FALCON trial was a phase III, randomized, double-blind, double-dummy, multicentre 
study to assess the efficacy and tolerability of fulvestrant 500 mg versus anastrozole 1 mg in 
postmenopausal women with HR+ LA/MBC who had not received prior endocrine therapy.  
The study design and results have been described previously [7]. Briefly, patients 
were randomized 1:1 to fulvestrant 500 mg (days 0, 14, 28, then every 28 days) or 
anastrozole 1 mg (once daily) until disease progression or discontinuation.  
The study was conducted in accordance with the ethical principles of the Declaration 
of Helsinki, the International Council on Harmonisation and Good Clinical Practice 
guidelines. The final protocol (NCT01602380) was approved by local ethics committees and 
institutional review boards at each study site, and all patients provided written informed 
consent. 
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2.2. HRQoL 
HRQoL was assessed at randomization and every 12 weeks during treatment by FACT-B 
questionnaire, which assesses multidimensional QoL using physical, emotional, social and 
functional well-being domains, plus a breast cancer subscale that contains items specific to 
QoL in patients with breast cancer [19]. FACT-B total score is a sum of all FACT-B subscale 
scores, and assesses overall HRQoL, with a scale range of 0 (low HRQoL) to 144 (high 
HRQoL). TOI is a sum of physical and functional well-being and breast cancer subscale 
scores, and represents an index of overall physical and functional wellbeing [19], with a scale 
range of 0 (low HRQoL) to 92 (high HRQoL). HRQoL data post-treatment (in patients with 
or without disease progression) were collected at 3 months post-treatment discontinuation 
and every 6 months thereafter.  
Compliance with FACT-B questionnaire completion (calculated as the number of 
patients with an evaluable baseline and at least one evaluable follow-up FACT-B form, 
divided by the number of patients expected to have completed at least the baseline form) was 
calculated over time, including data collected on treatment and post-treatment 
discontinuation. 
Mean changes from baseline in FACT-B total score and TOI, and improvement rates 
during treatment with fulvestrant and anastrozole, were calculated. Based on 
recommendations by Eton et al [20], changes from baseline in FACT-B total score of ≥+8 
points were classified as improved, ≤-8 points as deteriorated, and between -8 and +8 points 
as stable. Changes from baseline in TOI of ≥+6 points were classified as improved, ≤-6 
points as deteriorated, and between -6 and +6 points as stable. 
The TTD for HRQoL, based on FACT-B TOI or FACT-B total score, was defined as 
the interval from the date of randomization to the first assessment within the following 
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12 weeks of worsening without improvement in FACT-B TOI or FACT-B total score, or the 
date of death by any cause in the absence of deterioration. 
2.3. Statistical analysis 
A post-hoc mixed model repeated measures (MMRM) analysis (using baseline score as a 
covariate and study visit as a repeated measure) was performed to calculate the change from 
baseline in FACT-B total score and TOI in both treatment arms at every 12-week time point, 
and to estimate the overall treatment effect. The analysis included data collected after 
treatment discontinuation. The Kaplan-Meier method and the stratified log-rank test were 
performed to assess the TTD in FACT-B total score and TOI.  
Post-hoc exploratory analyses of the TTD of FACT-B total score and TOI according 
to baseline visceral disease status (yes/no) were also performed. Visceral disease was defined 
as patients with adrenal, bladder, central nervous system, oesophagus, liver, lung, 
peritoneum, pleura, renal, small bowel, stomach, pancreas, thyroid, colon, rectal, ovary, 
biliary tract, ascites, pericardial effusion, spleen or pleural effusion disease sites at baseline. 
3. Results 
3.1. Patients 
In total, 462 patients were randomized (fulvestrant, n = 230; anastrozole, n = 232). Of these, 
460 patients received treatment (fulvestrant, n = 228; anastrozole, n = 232). Patient 
demographics were broadly similar between the treatment arms (Table 1). The time from 
diagnosis to randomization was ≤1 year for the majority of patients (fulvestrant, 160/230 
[69.6%]; anastrozole, 165/232 [71.1%]) and most patients had metastatic disease 
(fulvestrant, 202/230 [87.8%]; anastrozole, 200/232 [86.2%]). 
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3.2. Compliance 
Overall compliance to the FACT-B questionnaire was 91.3% with fulvestrant (range 66.7–
94.3%) and 92.2% with anastrozole (range 60.0–97.4%) (Fig. 1). Decline in compliance was 
steady over time, with a similar rate of decline in both treatment arms. 
3.3. Change from baseline in FACT-B total score and TOI 
At baseline, the mean (standard deviation) FACT-B and TOI scores were high and similar in 
both fulvestrant and anastrozole treatment arms (FACT-B: 102.2 [16.93] and 101.1 [16.84], 
respectively; TOI: 63.9 [11.86] and 63.2 [11.89], respectively). Mean change from baseline in 
FACT-B total score and TOI remained broadly stable (approximately ± 3 points to week 132) 
and was similar between arms during treatment (Fig. 2). Mean change from baseline in 
FACT-B subscale data are presented in Supplementary Fig. 1, and are consistent with these 
findings. 
Results of the post-hoc MMRM analysis of the change from baseline in FACT-B total 
score and TOI are shown in Fig. 3. Overall, the adjusted mean change from baseline in 
FACT-B total score was -0.57 with fulvestrant (95% CI: -2.32–1.18) and -3.53 (95% CI: -
5.27, -1.78) with anastrozole (P = 0.019). For TOI, there was no overall adjusted mean 
change from baseline with fulvestrant (95% CI: -1.21–1.21); P = 0.09) versus a change of -
1.47 (95% CI: -2.67, -0.27) with anastrozole. The results of the MMRM analysis of change 
from baseline in FACT-B subscale data are presented in Supplementary Fig. 2; the overall 
adjusted mean change from baseline was not significantly different for fulvestrant versus 
anastrozole for all subscales apart from functional well-being (P = 0.007) and social well-
being (P = 0.001). 
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Approximately one-third of patients had improved FACT-B total score (from baseline 
up to week 120) and TOI (from baseline up to week 132) with fulvestrant (proportion of 
patients with improvement, ranges: 22.4–35.8% and 26.4–45.0%, respectively) and 
anastrozole (proportion of patients with improvement, ranges: 22.7–37.9% and 18.6–32.9%, 
respectively; Fig. 4). 
3.4. TTD 
Fig. 5 shows the Kaplan-Meier curves for the TTD in FACT-B total score and TOI with 
fulvestrant versus anastrozole. The median TTD in FACT-B total score was 13.8 months with 
fulvestrant compared with 11.1 months with anastrozole. There was no significant difference 
in TTD between the treatment arms (HR = 0.84; 95% CI: 0.66–1.07; P = 0.1594). The 
median TTD in TOI score was 13.8 months with fulvestrant compared with 11.1 months with 
anastrozole. There was no significant difference in TTD between the treatment arms 
(HR = 0.90; 95% CI: 0.70–1.15; P = 0.4008). 
The TTD of FACT-B total score and TOI numerically favoured fulvestrant compared 
with anastrozole in patients with visceral disease (median TTD FACT-B 13.8 months versus 
11.3 months, respectively; HR = 0.79; 95% CI: 0.56–1.11; median TTD TOI 16.1 months 
versus 13.3 months, respectively; HR = 0.85; 95% CI: 0.60–1.22) and non-visceral disease 
(median TTD 12.0 months versus 11.1 months, respectively; HR = 0.89; 95% CI: 0.62–1.27; 
median TTD TOI 13.7 months versus 11.1 months, respectively; HR = 0.98; 95% CI: 0.68–
1.42). 
4. Discussion 
The phase III randomized FALCON trial demonstrated improved PFS with fulvestrant 
500 mg versus anastrozole 1 mg in endocrine-naïve postmenopausal women with 
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HR+ LA/MBC (HR = 0.797; 95% CI: 0.637–0.999; P = 0.0486) [7]. The safety profile of 
fulvestrant and anastrozole was consistent with previous findings. 
The post-hoc analyses reported here evaluated additional HRQoL data in the 
FALCON study. HRQoL, determined by the mean change from baseline in TOI and FACT-B 
total score, was maintained during treatment with fulvestrant and anastrozole. Fulvestrant had 
a numerically longer median TTD over anastrozole for both FACT-B total score and TOI, 
and this treatment effect was also observed in patients with visceral and non-visceral disease. 
Similar proportions of patients had improved FACT-B total score and TOI with fulvestrant 
versus anastrozole.  
The results of the MMRM analysis suggest that, overall, there was a smaller decline 
in FACT-B total score from baseline (less of a reduction in HRQoL over time) with 
fulvestrant compared with anastrozole; however, the difference between the two treatments 
was small, and, as this was a post-hoc analysis, the results should be interpreted with caution. 
The heterogeneous nature of LA/MBC, and timing of the HRQoL assessments during 
the study, may also have impacted the results, particularly in patients with early progression. 
The majority of patients in the FALCON study presented with metastatic disease, with the 
overall visceral component as high as 55%; factors that have been shown to compromise 
HRQoL [21–24]. In addition, patients with a greater disease burden may experience 
symptoms leading to discontinuation, or may lack interest in completing HRQoL 
questionnaires due to progressive disease or the worsening of psychological symptoms, such 
as depression [25]. Furthermore, differences in treatment-related toxicities and 
discontinuations due to AEs could have explained why a significant improvement with 
fulvestrant in terms of PFS compared with anastrozole was observed, while the findings of 
this post-hoc analysis suggest that there was no difference in HRQoL between the two 
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treatment arms. However, while the incidence of AEs leading to treatment discontinuation 
was slightly higher in the fulvestrant arm compared with the anastrozole arm, there were no 
relevant differences between the treatment arms when AEs leading to discontinuation were 
considered at the preferred term level. The lack of difference in HRQoL observed in this 
study could possibly reflect the fact that both drugs are known to be well tolerated. It should 
be noted that the FALCON study was not powered to demonstrate a difference in HRQoL 
over time. 
Strengths of this study include the double-blind nature of study, which limits any bias 
in patient-reported outcome assessments. One limitation of this study, applicable to other 
studies of HRQoL [22], was the decline in completion of FACT-B questionnaires over time 
due to treatment discontinuation, which may have impacted the results if this was a 
consequence of disease severity or worsening HRQoL. However, overall compliance was 
high (>90%) and comparable in both treatment arms.  
No information on comorbidities, including those of a psychological nature, or post-
progression therapies after treatment discontinuation was collected; these factors may also 
have confounded the HRQoL findings. In addition, the post-hoc nature of this analysis limits 
the conclusions that can be made due to a lack of adjustment for multiplicity.  
Overall, the results of these post-hoc analyses suggest that HRQoL is maintained and 
comparable with fulvestrant versus anastrozole in postmenopausal patients with 
HR+ LA/MBC who did not receive prior endocrine therapy.  
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Table 1  
Patient disposition and demographics. 
 Fulvestrant  
500 mg 
Anastrozole  
1 mg 
Randomized, n (%) 230 (100.0) 232 (100.0) 
Received treatment, n (%) 228 (99.1) 232 (100.0) 
Discontinued treatment, n (%) 167 (73.2) 183 (78.9) 
Disease progression 134 (58.8) 158 (68.1) 
Adverse event 16 (7.0) 11 (4.7) 
Patient decision 10 (4.4) 10 (4.3) 
Severe non-compliance 3 (1.3) 1 (0.4) 
Lost to follow-up 1 (0.4) 0 (0.0) 
Other 3 (1.3) 3 (1.3) 
Age, years; median (range) 64 (38–87) 62 (36–90) 
Race   
White 175 (76.1) 174 (75.0) 
Asian 36 (15.7) 34 (14.7) 
Black or other 19 (8.3) 24 (10.3) 
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Figure legends 
Fig. 1. FACT-B compliance. 
FACT-B, Functional Assessment of Cancer Therapy for Breast Cancer. 
aNumber of patients still in the study at the specified time point. 
Compliance rate at each time point was calculated as the number of evaluable forms divided 
by the number of expected forms, multiplied by 100. Includes patients on treatment and those 
who had discontinued treatment. Overall compliance includes patients with an evaluable form 
at baseline and at least one post-baseline time point. 
 
Fig. 2. Mean (± SD) change from baseline in A) FACT-B total score and B) TOI (intention-
to-treat population) 
FACT-B, Functional Assessment of Cancer Therapy for Breast Cancer; SD, standard 
deviation; TOI, Trial Outcome Index. 
Depicts patients on treatment only. 
 
Fig. 3. MMRM analysis adjusted mean (± 95% CI) change from baseline in A) FACT-B total 
score and B) TOI. 
CI, confidence interval; FACT-B, Functional Assessment of Cancer Therapy for Breast 
Cancer; MMRM, mixed model repeated measures; TOI, Trial Outcome Index. 
 
Fig. 4. Percentage of patients with improved, stable or deteriorated A) FACT-B total score 
and B) TOI during treatment. 
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FACT-B, Functional Assessment of Cancer Therapy for Breast Cancer; TOI, Trial Outcome 
Index. 
Time points with ≥20 patients in each arm are shown. The denominator in the percentage 
calculations includes the patients who were not evaluable at each visit. 
 
Fig. 5. Kaplan-Meier curve of TTD of A) FACT-B total score and B) TOI. 
FACT-B, Functional Assessment of Cancer Therapy for Breast Cancer; TOI, Trial Outcome 
Index, TTD, time to deterioration.  
TTD was defined as the time from randomization to worsening in the FACT-B total score or 
TOI (without improvement in the following 12 weeks), or the date of death (any cause). 
 
Supplementary Fig 1. Mean (± SD) change from baseline in A) physical well-being, 
B) functional well-being, C) social well-being, D) emotional well-being and E) breast cancer 
subscale FACT-B subscale scores. 
FACT-B, Functional Assessment of Cancer Therapy for Breast Cancer; 
SD, standard deviation. 
 
Supplementary Fig. 2. MMRM analysis adjusted mean (± 95% CI) change from baseline in 
A) physical well-being, B) functional well-being, C) social well-being, D) emotional well-
being and E) breast cancer subscale FACT-B subscale scores. 
CI, confidence interval; FACT-B, Functional Assessment of Cancer Therapy for Breast 
Cancer; MMRM, mixed model repeated measures.  
